CN104321300A - 脂肪酸的2-羟基衍生物的对映体 - Google Patents

脂肪酸的2-羟基衍生物的对映体 Download PDF

Info

Publication number
CN104321300A
CN104321300A CN201280060748.XA CN201280060748A CN104321300A CN 104321300 A CN104321300 A CN 104321300A CN 201280060748 A CN201280060748 A CN 201280060748A CN 104321300 A CN104321300 A CN 104321300A
Authority
CN
China
Prior art keywords
enzyme
level
2ohoa
cancer
levels
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280060748.XA
Other languages
English (en)
Chinese (zh)
Inventor
巴勃罗比森特·埃斯克里瓦鲁伊斯
格温多林·巴塞罗科贝利恩
玛利亚劳拉·马丁
西尔维娅·特雷斯希门尼斯
玛利亚安东尼娅·诺格拉萨尔瓦
哈维尔·巴斯奎兹哈乌比特
戴维·洛佩兹希门尼斯
马伊塔恩·伊巴尔古伦艾斯皮塔尔特
何塞哈维尔·索托萨尔瓦多
米格尔·尤斯阿斯蒂斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitat de les Illes Balears
Original Assignee
Universitat de les Illes Balears
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitat de les Illes Balears filed Critical Universitat de les Illes Balears
Publication of CN104321300A publication Critical patent/CN104321300A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/42—Separation; Purification; Stabilisation; Use of additives
    • C07C51/487—Separation; Purification; Stabilisation; Use of additives by treatment giving rise to chemical modification
    • C07C51/493—Separation; Purification; Stabilisation; Use of additives by treatment giving rise to chemical modification whereby carboxylic acid esters are formed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201280060748.XA 2011-10-07 2012-10-08 脂肪酸的2-羟基衍生物的对映体 Pending CN104321300A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
ES201131622 2011-07-10
ES201131622A ES2401629B1 (es) 2011-10-07 2011-10-07 Enantiómeros de 2-hidroxiderivados de ácidos grasos y su uso como medicamentos.
US201261610762P 2012-03-14 2012-03-14
US61/610,762 2012-03-14
PCT/ES2012/070697 WO2013050644A1 (es) 2011-10-07 2012-10-08 Enantiómeros de 2-hidroxiderivados de ácidos grasos

Publications (1)

Publication Number Publication Date
CN104321300A true CN104321300A (zh) 2015-01-28

Family

ID=48043212

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280060748.XA Pending CN104321300A (zh) 2011-10-07 2012-10-08 脂肪酸的2-羟基衍生物的对映体

Country Status (12)

Country Link
US (1) US9359281B2 (enExample)
EP (2) EP3287437B1 (enExample)
JP (1) JP2014530806A (enExample)
CN (1) CN104321300A (enExample)
DK (1) DK2774910T3 (enExample)
ES (3) ES2401629B1 (enExample)
HU (1) HUE035430T2 (enExample)
IN (1) IN2014CN03111A (enExample)
PL (1) PL2774910T3 (enExample)
PT (1) PT2774910T (enExample)
RU (2) RU2687967C2 (enExample)
WO (1) WO2013050644A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2345241B1 (es) * 2009-03-16 2011-09-08 Lipopharma Therapeutics Uso de 2-hidroxiderivados de acidos grasos poliinsaturados como medicamentos.
AU2015334964B2 (en) * 2014-10-21 2019-06-20 Universitat De Les Illes Balears Method for the synthesis of hydroxy-triglycerides and uses thereof for the prevention and treatment of diseases
HUE063275T2 (hu) * 2017-05-16 2024-01-28 Ability Pharmaceuticals S A Gyógyszerészeti kombináció rákbetegség kezelésére
WO2019099664A1 (en) * 2017-11-16 2019-05-23 The Research Foundation For The State University Of New York Use of 2-hydroxyoleic acid for the treatment of systemic lupus erythematosus and other immune pathologies
ES2846824B2 (es) * 2020-01-29 2022-01-19 Univ Illes Balears Profarmacos de acidos grasos poliinsaturados y usos medicos de los mismos
ES2911474B2 (es) * 2020-11-17 2023-02-06 Univ Illes Balears Profarmacos de acidos grasos monoinsaturados y sus metabolitos: usos medicos y como biomarcadores
AU2021212330A1 (en) * 2020-01-29 2022-09-22 Universitat De Les Illes Balears Alpha-hydroxylated fatty-acid metabolites, medical uses of same and use as biomarkers
KR20220140723A (ko) * 2020-02-10 2022-10-18 어빌리티 파마슈티컬스 에스.엘. 암의 치료를 위한 약제학적 조합
WO2024063611A2 (ko) * 2022-09-23 2024-03-28 박진병 지방산 수용체를 강하게 활성화시키는 장쇄 지방산 또는 이의 유도체
ES2982396A1 (es) * 2023-03-14 2024-10-15 Veritas Therapeutics S L 2-hidroxi-octadecen-9-cis-oato para uso en el tratamiento de patologias oncologicas y del dolor neuropatico

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1688302A (zh) * 2001-10-11 2005-10-26 巴利阿里群岛大学 羟油酸及相关化合物在制备药物中的应用
CN102356057A (zh) * 2009-03-16 2012-02-15 利波法玛治疗公司 多不饱和脂肪酸的衍生物作为药物的用途
CN102355897A (zh) * 2008-12-09 2012-02-15 巴利阿里群岛大学 用作药物的顺式单不饱和脂肪酸的α-衍生物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2235541C2 (ru) * 1994-10-04 2004-09-10 Эмори Юниверсити Лечение атеросклероза и других сердечно-сосудистых и воспалительных заболеваний
AUPR547601A0 (en) * 2001-06-05 2001-06-28 Carcraft Qld Pty Ltd Tab with writing surface

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1688302A (zh) * 2001-10-11 2005-10-26 巴利阿里群岛大学 羟油酸及相关化合物在制备药物中的应用
CN102355897A (zh) * 2008-12-09 2012-02-15 巴利阿里群岛大学 用作药物的顺式单不饱和脂肪酸的α-衍生物
CN102356057A (zh) * 2009-03-16 2012-02-15 利波法玛治疗公司 多不饱和脂肪酸的衍生物作为药物的用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
W. ADAM ET AL.: "Synthesis of Optically Active α-Hydroxy Acids by Kinetic Resolution Through Lipase-Catalyzed Enantioselective Acetylation", 《EUR. J. ORG. CHEM.》, 31 December 1998 (1998-12-31), pages 2013 - 2018 *

Also Published As

Publication number Publication date
EP2774910A1 (en) 2014-09-10
RU2017141446A (ru) 2019-02-13
IN2014CN03111A (enExample) 2015-07-03
RU2687967C2 (ru) 2019-05-17
RU2017141446A3 (enExample) 2019-02-13
EP3287437A1 (en) 2018-02-28
ES2401629A1 (es) 2013-04-23
RU2014118123A (ru) 2015-11-20
US9359281B2 (en) 2016-06-07
EP2774910A4 (en) 2015-02-25
ES2773784T3 (es) 2020-07-14
WO2013050644A1 (es) 2013-04-11
ES2401629B1 (es) 2014-03-04
ES2653675T3 (es) 2018-02-08
RU2637937C2 (ru) 2017-12-08
HUE035430T2 (en) 2018-05-02
DK2774910T3 (en) 2018-01-08
JP2014530806A (ja) 2014-11-20
US20140288176A1 (en) 2014-09-25
EP3287437B1 (en) 2019-12-11
EP2774910B1 (en) 2017-09-27
PL2774910T3 (pl) 2018-03-30
PT2774910T (pt) 2018-01-03

Similar Documents

Publication Publication Date Title
CN104321300A (zh) 脂肪酸的2-羟基衍生物的对映体
JP2014530806A5 (enExample)
KR102233102B1 (ko) 고도불포화 지방산 유도체의 의약으로서 용도
JP6506206B2 (ja) Ｐｕｆａ誘導体による酸化ストレス障害の緩和
Igarashi et al. Disturbed choline plasmalogen and phospholipid fatty acid concentrations in Alzheimer's disease prefrontal cortex
Jo et al. Peroxisomal dysfunction in neurodegenerative diseases
Rojas et al. Gene expression analysis in human fetal retinal explants treated with docosahexaenoic acid
KR20200027545A (ko) 지방산 유도체 및 이의 용도
EA010802B1 (ru) Оксилипины из полиненасыщенных жирных кислот с длинной цепью и способы их получения и применения
Gentile et al. Role of cytosolic calcium-dependent phospholipase A2 in Alzheimer's disease pathogenesis
CA2442683A1 (en) Methods, compounds, and compositions for reducing body fat and modulating fatty acid metabolism
Wolozin et al. The cellular biochemistry of cholesterol and statins: insights into the pathophysiology and therapy of Alzheimer's disease
JP2012519199A (ja) 哺乳動物における内因性プラスマローゲンレベルを上昇させる方法
EP2539709B1 (en) Alzheimer's disease-specific alterations of protein kinase c epsilon (pkc-epsilon) protein levels
US20220151973A1 (en) Halogenated esters of cyclopropanated unsaturated fatty acids for use in the treatment of neurodegenerative diseases
JP2015501426A (ja) 注意欠陥多動障害を処置するまたは予防する方法および組成物
Morito et al. Fatty acid metabolism in peroxisomes and related disorders
CA2477604A1 (en) Modulation of protein methylation and phosphoprotein phosphate
Du et al. β-oxidation modulates metabolic competition between eicosapentaenoic acid and arachidonic acid regulating prostaglandin E2 synthesis in rat hepatocytes–Kupffer cells
Calviello et al. Alzheimer's disease and n-3 polyunsaturated fatty acids: beneficial effects and possible molecular pathways involved
RU2441061C2 (ru) Производные докозагексаеновой кислоты и их применение в качестве лекарственных средств
Rojas Baechler et al. Gene Expression Analysis in Human Fetal Retinal Explants Treated with Docosahexaenoic Acid
Aubourg et al. Pediatric Neurology Part III: Chapter 163. Peroxisomal disorders
JP2018505889A (ja) アテローム形成を治療するためのシステムおよび方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB03 Change of inventor or designer information

Inventor after: ESCRIBA RUIZ PABLO VICENTE

Inventor after: Martin Maria Laura

Inventor after: NOGUERA SALVA MARIA ANTONIA

Inventor after: BUSQUETS XAUBET XAVIER

Inventor after: LOPEZ JIMENEZ DAVID

Inventor after: IBARGUREN AIZPITARTE MAITANE

Inventor after: SOTO SALVADOR JOSE JAVIER

Inventor after: YUS ASTIZ MIGUEL

Inventor before: ESCRIBA RUIZ PABLO VICENTE

Inventor before: YUS ASTIZ MIGUEL

Inventor before: BARCELO COBLIJN GWNDOLYN

Inventor before: Martin Maria Laura

Inventor before: TERES JIMENEZ SILVIA

Inventor before: NOGUERA SALVA MARIA ANTONIA

Inventor before: BUSQUETS XAUBET XAVIER

Inventor before: LOPEZ JIMENEZ DAVID

Inventor before: IBARGUREN AIZPITARTE MAITANE

Inventor before: SOTO SALVADOR JOSE JAVIER

COR Change of bibliographic data

Free format text: CORRECT: INVENTOR; FROM: ESCRIBA RUIZ PABLO VICENTE BARCELO COBLIJN GWNDOLYN MARTIN MARIA LAURA TERES JIMENEZ SILVIA? NOGUERA SALVA MARIA ANTONIA BUSQUETS XAUBET XAVIER LOPEZ JIMENEZ DAVID IBARGUREN AIZPITARTE MAITANE SOTO SALVADOR JOSE JAVIER YUS ASTIZ MIGUEL TO: ESCRIBA RUIZ PABLO VICENTE MARTIN MARIA LAURA NOGUERA SALVA MARIA ANTONIA BUSQUETS XAUBET XAVIER LOPEZ JIMENEZ DAVID IBARGUREN AIZPITARTE MAITANE SOTO SALVADOR JOSE JAVIER YUS ASTIZ MIGUEL

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150128